ProCE Banner Series

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

Interact with an expert during a 1-hour, CME/CE-certified live meeting  focused on best practices and emerging strategies in the use of BTK inhibitors to treat relapsed/refractory CLL/SLL and MCL. Register today!

To Register: On the events dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar. 

  AAPA
  | ACPE
  | AMA
  | ANCC
Credits Available

1.0

Who Should Attend

This program is intended for hematologists, medical oncologists, nurse practitioners, physician associates/physician assistants, pharmacists, nurses, and other healthcare professionals who care for patients with CLL/SLL or MCL.

All Events

Upcoming Events

May

03

2024

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes [Open Registration]

7:30 AM - 8:30 AM Eastern Time (ET)

Virtual

CCO Simulcast, Hendersonville, North Carolina

Past Events

October

30

2023

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

11:00 AM - 12:00 PM Central Time (CT)

Virtual

Private Event, Mobile, Alabama

November

01

2023

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

6:30 PM - 7:30 PM Eastern Time (ET)

Virtual

Private Event, Queens, New York

November

15

2023

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

5:30 PM - 6:30 PM Alaska Standard Time Zone (AK)

Virtual

Private Event | Virtual Group AK, Anchorage, Alaska

November

15

2023

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

7:00 PM - 8:00 PM Pacific Time (PT)

In-person

Private Event | Host Group at The Grille, Danville, California

November

28

2023

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event | Virtual Group, Norman, Oklahoma

December

05

2023

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

7:30 AM - 8:30 AM Pacific Time (PT)

Virtual

Private Event, Post Falls, Idaho

December

06

2023

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Private Event, Plattsburgh, New York

January

18

2024

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event | Host Group in Congers, Congers, New York

January

30

2024

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

3:00 PM - 4:00 PM Eastern Time (ET)

Virtual

Private Event, Georgetown, South Carolina

March

18

2024

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes [Open Registration]

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

CCO Simulcast, Columbia, South Carolina

April

08

2024

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes [Open Registration]

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast, Baltimore, Maryland

Faculty

ProCE Banner Faculty
Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

ProCE Banner Faculty
Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

ProCE Banner Faculty
Farrukh T. Awan, MD

Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program

Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

ProCE Banner Faculty
Jonathan J. Cohen, MD

Voluntary Associate Professor of Medicine
Division of Hematology/Oncology
University of Miami School of Medicine
Miami, Florida

ProCE Banner Faculty
Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

ProCE Banner Faculty
Nirav Shah, MD

Associate Professor of Medicine
Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin

Topics

  • Current BTK inhibitor indications and guideline recommendations for R/R CLL and MCL
    o    Mechanisms of action
    o    Comparative efficacy and safety profiles
    o    Emerging data
  • Case challenges: selecting and sequencing BTK inhibitor therapy in R/R CLL/SLL and R/R MCL 
  • Clinical pearls and insights
  • The future of BTK inhibitor therapy: emerging strategies and approvals

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners to optimize treatment with BTK inhibitors in caring for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL.

Target Audience
This program is intended for hematologists, medical oncologists, nurse practitioners, physician associates/physician assistants, pharmacists, nurses, and other healthcare professionals who care for patients with CLL/SLL or MCL. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate differences between covalent and noncovalent BTKi in terms of molecular characteristics, selectivity, clinical data, approved indications, dosing, safety profiles, and efficacy and their respective impact on clinical practice
  • Plan BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL, taking into consideration current indications, expert and guideline recommendations, and recent practice-changing clinical trial evidence
  • Implement evidence-based therapy for patients with resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes
  • Optimally manage adverse events associated with BTKi-based therapies considering safety profiles unique to each agent and regimen
  • Identify patients with R/R MCL and R/R SLL/SLL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations 

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-218-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate/Physician Assistant Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

This activity is supported by an educational grant from Lilly.